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Key Points
• Similar event-free sur-
vival after HLA-matched
sibling andHLA-matched
unrelated donor
transplant.
•High graft failure after
HLA-mismatched re-
lated donor transplant.
Westudied1110patientswithb-thalassemiamajor aged#25 years who received transplants
with grafts fromHLA-matched related (n5 677; 61%), HLA-mismatched related (n5 78; 7%),
HLA-matched unrelated (n 5 252; 23%), and HLA-mismatched unrelated (n 5 103; 9%)
donors between 2000 and 2016. Ninety percent of transplants were performed in the last
decade. Eight-ﬁve percent of patients received$20 transfusions and 88%were inadequately
chelated. All patients received myeloablative-conditioning regimen. Overall and event-free
survival were highest for patients aged #6 years and after HLA-matched related and
HLA-matched unrelated donor transplantation. The 5-year probabilities of overall survival
for patients aged #6 years, 7 to 15 years, and 16 to 25 years, adjusted for donor type and
conditioning regimen were 90%, 84%, and 63%, respectively (P , .001). The corresponding
probabilities for event-free survival were 86%, 80%, and 63% (P , .001). Overall and event-
free survival did not differ between HLA-matched related and HLA-matched unrelated
donor transplantation (89% vs 87% and 86% vs 82%, respectively). Corresponding
probabilities after mismatched related and mismatched unrelated donor transplantation
were 73% vs 83% and 70% vs 78%. In conclusion, if transplantation is considered as
a treatment option it should be offered early (age #6 years). An HLA-matched unrelated
donor is a suitable alternative if an HLA-matched relative is not available.
Introduction
b-thalassemia major is a genetic defect that is associated with absent or impaired b-globin synthesis
resulting in an imbalanced accumulation of a-globin chains and ineffective erythropoiesis with
hemolysis.1 The hallmarks of supportive care include regular red blood cell transfusion with iron
chelation therapy for transfusion-related iron overload.2 Allogeneic hematopoietic cell transplantation is
a curative option for b-thalassemia major and ;70% of transplants in the last decade used HLA-
matched sibling donors.3 The availability of an HLA-matched sibling donor and transplantation-related
risks (graft failure, acute and chronic graft-versus-host disease [GVHD]) has limited the broad use
of allogeneic transplantation. In recent years, there has been an increase in the number of
transplants from alternative donors and use of novel transplant-conditioning regimens to lower
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transplantation-related risks.4-8 A myeloablative dose of busulfan
(Bu) with cyclophosphamide (Cy) used to be the predominant con-
ditioning regimen. Although most conditioning regimens in recent
years are also myeloablative in intensity, modifications include the
addition of fludarabine (FLU) and/or thiotepa (TT) to Bu and Cy or
treosulfan with FLU and/or TT with favorable outcomes.4-6
In addition to donor type and transplant-conditioning regimen,
the timing of transplantation is also a significant contributor to
the success of allogeneic transplantation for thalassemia. The
Pesaro risk class that was developed over 30 years ago for chil-
dren with b-thalassemia recorded higher mortality for those with risk
class II and III compared with class I.9 Risk class was assigned
based on the presence or absence of hepatomegaly and portal
fibrosis. However, a liver biopsy that is needed to ascertain the
presence or absence of portal fibrosis is not obtained for all patients
who receive allogeneic transplantation. This could in part be attributed
to: practice variation between geographic regions or transplant centers
within a geographic region, morbidity, and a rare risk of mortality
associated with the procedure, or a perception that risk class
assignment is a prognostic tool unlikely to alter the decision to
proceed to transplantation. Consequently, others have studied
clinical risk factors associated with transplantation and recorded
higher mortality in patients older than 6 years at transplantation
and those with hepatomegaly at transplantation10,11 However, in
both reports, age and hepatomegaly correlated with Pesaro risk
class, implying that these clinical factors may be used to ascertain
mortality risks when a liver biopsy is not obtained.
The recent reports on improved outcomes after allogeneic trans-
plantation for thalassemia,4-7 with the exception of the report from
the European Society for Blood and Marrow Transplantation (EBMT),3
included modest numbers of patients. The EBMT report studied the
period 2000 to 2010, and included predominantly HLA-matched
sibling donor transplants and patients aged,18 years. That report did
not study outcomes for alternative donor transplantation.3 There-
fore, in the current analyses, we sought to address outcomes after
transplantation in children and young adults (age #25 years) and
use of alternative donors relative to HLA-matched related donor
transplantation in 3 geographic regions: China, India, and the United
States. Although our study period included 2000 to 2016, 90% of
transplants occurred between 2006 and 2016 thus representing
current practice patterns.
Patients and methods
Data source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) is a working group of .300 transplant centers that con-
tribute data on consecutive allogeneic and autologous transplants.
Fifty transplant centers in China, India, and the United States
contributed data for the study. Patients are followed longitudinally
until death or loss to follow-up. Accuracy of data reported to the
CIBMTR and compliance is monitored by on-site audits. Consent is
sought from patients and/or their legal guardians for research. The
institutional review board of the National Marrow Donor Program
approved the study.
Patients
Eligible were 1110 patients with b-thalassemia major aged#25 years
who received their first allogeneic hematopoietic cell transplant
between 2000 and 2016. Ninety percent of transplants were
performed in the last decade. All patients received myeloablative-
conditioning regimens and most regimens included Bu (dose
$8.4 mg/kg and dose titrated based on pharmacokinetics).12 Two
hundred fifteen patients (19%) have been reported previously.
Excluded were patients aged .25 years (n 5 1) and reduced-
intensity conditioning regimen transplantation (n 5 23).
Outcomes
The primary outcome was event-free survival (death from any cause
or graft failure). Graft failure was defined as: failure to achieve absolute
neutrophil recovery (ANC) $0.5 3 109/L for 3 consecutive days;
ANC decline to,0.53 109/L without recovery after having achieved
ANC $0.5 3 109/L; myeloid donor chimerism (,5%); recurrence
of transfusion dependence; or second transplant.13 Other out-
comes studied were overall survival (death from any cause),
neutrophil recovery (absolute neutrophil count, $0.5 3 109/L;
and donor chimerism, .5%) and platelet recovery ($20 3 109/L
unsupported for 7 days), and acute and chronic GVHD graded
using standard criteria.14,15 Surviving patients were censored at
last follow-up.
Statistical methods
The probabilities of event-free survival and overall survival were
calculated using the Kaplan-Meier estimator.16 The probability of
graft failure was calculated using the cumulative incidence estima-
tor to accommodate competing risks.17 Risk factors associated
with event-free survival and overall survival were examined using the
Cox proportional hazards model.18 Risk factors associated with
graft failure and acute and chronic GVHD were examined using the
Fine and Gray model.19 Variables considered included age, sex, red
blood cell transfusion, adequacy of iron chelation, serum ferritin,
hepatomegaly, donor type, graft type, conditioning regimen, in vivo
T-cell depletion, GVHD prophylaxis, and transplant period (Table 1).
The age groups (#6 years vs 7-15 years vs 16-25 years) were
determined statistically as the optimal cut points in the Cox
regression model for overall survival. Models were built using
stepwise forward selection and variables that met a significance
level of$0.05 were held in the final model. There were no first-order
interactions between the variables held in the final models. An effect
of transplant center on survival was tested using the frailty model.20
All P values are 2-sided and all analyses were done using SAS
version 9.3 (Cary, NC).
Results
Patient, disease, and transplant characteristics
The characteristics of the 1110 children, adolescents, and young
adults are presented in Table 1. The median age at transplantation
was 6 years (range, ,1-25 years). Although the cohort included
young adults, they represent only 3% of the study population.
All patients were on a chronic transfusion program at time of
transplantation. Over one-half of patients had received over 50 red
blood cell transfusions and almost 90% of patients were inade-
quately chelated. Adequacy of chelation was defined as daily
chelation for at least 5 days per week beginning within 2 years
of regular transfusion. Approximately one-half of patients had
a serum ferritin $2500 ng/mL and over 70% of patients were
recorded to have hepatomegaly. In a subset (526 of 1110; 47%),
liver biopsy was obtained prior to transplantation to ascertain
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presence or absence of portal fibrosis. Consequently, we were
able to assign Pesaro risk class for this subset: risk class I
(39%), II (8%), and III (54%). All patients received nonirradiation
myeloablative-conditioning regimens. Thirty-four percent of patients
received Bu (8.4-13.2 mg/kg) plus Cy (100-120 mg/kg) plus TT
(5 mg/kg) plus FLU (200 mg/m2), 23% received Bu (11.2-17.6 mg/kg)
plus Cy (100-120 mg/kg) plus FLU (200 mg/m2), 22% received Bu
(16 mg/kg) plus Cy (200 mg/kg), 15% received treosulfan (42 mg/m2)
plus TT (8 mg/kg) plus FLU (120 mg/m2), and the remaining 5%
received Bu (12 or 16 mg/kg) or melphalan (140 mg/m2) plus FLU
(150-180 mg/m2) plus or minus TT (8-10 mg/kg). Bu dose was
titrated based on pharmacokinetics for all transplants that included
a Bu-containing regimen. In vivo T-cell depletion with antithymocyte
globulin was common (75% of transplants). Donor, graft, and
GVHD prophylaxis were confounded with transplant-conditioning
regimen. For the Bu/Cy and treosulfan/TT/FLU regimens, the pre-
dominant donor type was matched related donor (85%). Peripheral
blood was the predominant graft associated with Bu/Cy/TT/FLU-, Bu/
Cy/FLU-, and treosulfan/TT/FLU-conditioning regimens. All patients
Table 1. Patient and transplant characteristics
No. (%)
Age at transplantation, y
#6 638 (57)
7-15 439 (40)
16-25 33 (3)
Sex
Male/female 696 (63)/414 (37)
Red blood cell transfusions prior to transplantation
,20 40 (4)
20-50 304 (27)
.50 634 (57)
Not reported 132 (12)
Iron chelation
Adequate 117 (11)
Inadequate 981 (88)
Not reported 12 (1)
Hepatomegaly
Absent 280 (25)
Present 806 (73)
Not reported 24 (2)
Donor type
HLA-matched relative 677 (61)
HLA-mismatched relative 78 (7)
HLA-matched unrelated 252 (23)
HLA-mismatched unrelated 103 (9)
Graft type
Bone marrow 321 (29)
Peripheral blood 682 (61)
Cord blood 107 (10)
In vivo T-cell depletion
Yes/none 827 (75)/283 (25)
Conditioning regimen
BU/Cy/TT/FLU 376 (34)
BU/Cy/FLU 259 (23)
BU/Cy 249 (22)
Treosulfan/TT/FLU 169 (15)
BU or melphalan 6 TT 6 FLU 57 (5)
GVHD prophylaxis
Calcineurin inhibitor/methotrexate/mycophenolate 187 (17)
Calcineurin inhibitor/methotrexate 446 (40)
Calcineurin inhibitor/mycophenolate 350 (32)
Calcineurin inhibitor alone 31 (3)
Posttransplant Cy/cyclosporine/mycophenolate 96 (9)
Table 2. Risks factors for event-free survival and overall survival
Outcomes Events/evaluable HR (95% CI) P
Event-free survival
Age at transplantation, y
#6 84/638 1.00 ,.001
7-15 87/439 1.46 (1.07-2.00) .017
16-25 14/33 3.03 (1.68-5.47) ,.001
Donor type
HLA-matched relative 108/677 1.00 ,.001
HLA-mismatched relative 29/78 2.75 (1.81-4.16) ,.001
HLA-matched unrelated 26/252 1.25 (0.75-2.07) .39
HLA-mismatched unrelated 22/103 1.60 (0.95-2.71) .08
Conditioning regimen
Bu/Cy/TT/FLU 28/376 1.00 ,.001
Bu/Cy/FLU 27/259 1.32 (0.78-2.25) .31
Bu/Cy 71/249 3.11 (1.80-5.40) ,.001
Treosulfan/TT/FLU 38/169 2.79 (1.61-4.83) ,.001
Bu or melphalan 6 TT 6 FLU 21/57 5.09 (2.81-9.21) ,.001
Transplant period
2012-2016 74/657 1.00 .008
2006-2011 73/339 1.66 (1.17-2.35) .01
2000-2005 38/114 1.96 (1.16-3.33) .01
Overall survival
Age at transplantation, y
#6 57/638 1.00 ,.001
7-15 73/439 1.84 (1.29-2.63) ,.001
16-25 12/33 4.35 (2.28-8.30) ,.001
Donor type
HLA-matched relative 83/677 1.00 ,.001
HLA-mismatched relative 25/78 3.30 (1.93-4.77) ,.001
HLA-matched unrelated 19/252 1.13 (0.64-2.02) .67
HLA-mismatched unrelated 15/103 1.56 (0.85-2.88) .16
Conditioning regimen
Bu/Cy/TT/FLU 25/376 1.00 ,.001
Bu/Cy/FLU 22/259 1.32 (0.74-2.34) .34
Bu/Cy 55/249 3.61 (2.15-6.07) ,.001
Treosulfan/TT/FLU 30/169 2.22 (1.23-4.030 .008
Bu or melphalan 6 TT 6 FLU 10/57 2.55 (1.18-5.50) .02
2564 LI et al 10 SEPTEMBER 2019 x VOLUME 3, NUMBER 17
.For personal use only on October 1, 2019. at CHILDRENS HOSP MED CNTR www.bloodadvances.orgFrom 
received calcineurin inhibitor–containing regimens for GVHD pro-
phylaxis and ,10% of GVHD prophylaxis included posttransplant
Cy. This GVHD prophylaxis regimen was used exclusively with the
Bu/Cy/FLU regimen. Fifty-nine percent of transplants (657 of 1110)
were performed in 2012 to 2016, 31% (339 of 1110) were
performed in 2006 to 2011, and 10% (114 of 1110) were
performed in 2000 to 2005. The median follow-up of surviving
patients was 48 months (range, 3-193 months).
Event-free survival
Event-free survival was lower in patients older than 6 years at
transplantation compared with those aged #6 years, recipients
of HLA-mismatched related compared with HLA-matched related
donor transplant, and transplant period prior to 2012 (Table 2).
Among patients older than 6 years, event-free survival was lower
for patients aged 16 to 25 years compared with those aged 7 to
15 years (hazard ratio [HR], 2.08; 95% confidence interval [CI],
1.16-3.70; P 5 .01). Event-free survival was also lower after
HLA-mismatched related donor compared with HLA-matched
unrelated donor (HR, 2.20; 95% CI, 1.20-4.01; P 5 .01). Event-
free survival did not differ between HLA-mismatched related and
HLA-mismatched unrelated donor transplants (HR, 1.72; 95% CI,
0.92-3.20; P 5 .09). The 5-year probabilities of event-free survival
by age and donor type are shown in Figure 1 and Table 3. Although
all patients received myeloablative regimens, event-free survival was
lower with conditioning regimens other than Bu/Cy/TT/FLU com-
pared with Bu/Cy, treosulfan/TT/FLU and Bu or melphalan plus or
minus TT plus or minus FLU (Table 2). Similarly, compared with the
Bu/Cy/FLU regimen, event-free survival was lower after Bu/Cy (HR,
2.38; 95% CI, 1.39-4.00; P 5 .002), treosulfan/TT/FLU (HR, 2.13;
95% CI, 1.22-3.70; P 5 .008), and Bu or melphalan plus or minus
TT plus or minus FLU (HR, 3.85; 95% CI, 2.13-7.14; P , .0001)
regimens. Event-free survival did not differ between Bu/Cy/TT/FLU
and Bu/Cy/FLU regimens (Table 2). The effect of conditioning
regimen was independent of donor type. Additionally, among
recipients of unrelated donor transplantation, event-free survival
did not differ between the 2 predominant regimens: Bu/Cy/TT/
FLU and Bu/Cy/FLU (91% [95% CI, 86-95] and 89% [95% CI,
83-94], respectively). The 5-year probabilities of event-free survival
for patients aged #6 years, 7 to 15 years, and 16 to 25 years,
adjusted for donor type and conditioning regimen were 86% (95% CI,
83-89), 80% (95%CI, 76-84), and 63% (95%CI, 48-78), respectively
(P , .001).
Overall survival
Age at transplantation was associated with overall survival. Com-
pared with patients aged #6 years, survival was lower for patients
aged 7 to 15 years and 16 to 25 years at transplantation (Table 2).
Among patients older than 6 years at transplantation, survival was
lower in patients aged 16 to 25 years compared with 7 to 15 years
(HR, 2.38; 95% CI, 1.27-4.35; P 5 .006). Donor type was also
associated with survival. Survival was lower after HLA-mismatched
related donor compared with HLA-matched related donor (Table 2)
and HLA-matched unrelated donor (HR, 2.38; 95% CI, 1.70-4.35;
P 5 .006). Survival did not differ between HLA-matched unrelated
and HLA-matched related (Table 2) and HLA-mismatched unre-
lated donor transplants (HR, 1.37; 95% CI, 0.67-2.78; P 5 .38).
Years
0 2 51 3 4
p0.001
Age 6 years
Age 7-15 years
Age 16-25 yearsP
ro
ba
bil
ity
, %
100
0
20
40
60
80
A
Years
0 2 51 3 4
p0.001
Matched relative
Matched unrelated
Mismatched relative
Mismatched unrelated
100
0
20
40
60
80
B
Figure 1. Event-free survival. (A) Event-free survival
by age at transplantation. The 5-year probabilities of
event-free survival for patients aged #6 years, 7 to
15 years, and 16 to 25 years were 86% (83% to
89%), 80% (76% to 84%), and 63% (48% to 78%),
respectively. (B) Event-free survival by donor type.
The 5-year probabilities of event-free survival after
HLA-matched relative, HLA-mismatched relative,
HLA-matched unrelated, and HLA-mismatched
unrelated donor transplants were 86% (83% to 88%),
70% (61% to 79%), 82% (75% to 89%), and 78%
(70% to 86%), respectively.
Table 3. Five-year probabilities of event-free and overall survival by
age and donor type
Donor type
Event-free survival
(95% CI), %
Overall survival
(95% CI), %
Age, £6 y
HLA-matched relative 88 (84-91) 92 (89-95)
HLA-mismatched relative 73 (59-86) 75 (61-87)
HLA-matched unrelated 89 (83-93) 93 (88-96)
HLA-mismatched unrelated 83 (73-91) 89 (81-96)
Age, 7-15 y
HLA-matched relative 80 (75-85) 84 (79-88)
HLA-mismatched relative 56 (39-73) 62 (44-78)
HLA-matched unrelated 89 (82-95) 91 (83-97)
HLA-mismatched unrelated 71 (54-85) 79 (63-91)
Patients aged 16-25 years: N 5 24 patients who received HLA-matched related donor
transplantation with event-free survival of 58% (14 of 24) and overall survival of 63% (15 of
24). N 5 4 patients received HLA-mismatched related donor transplantation and only
2 patients are alive. N 5 4 patients received HLA-matched unrelated donor transplantation
and all patients are alive. N 5 1 patient received HLA-mismatched unrelated donor
transplantation and is death.
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The 5-year probabilities of overall survival by age and donor type
are shown in Figure 2 and Table 3. Overall survival was also
associated with conditioning regimen. Compared with the Bu/Cy/
TT/FLU regimen, survival was lower after other regimens except
Bu/Cy/FLU (Table 2). Similarly, compared with the Bu/Cy/FLU
regimen, survival was lower after Bu/Cy (HR, 2.70; 95% CI,
1.62-4.76; P 5 .0002) and treosulfan/TT/FLU (HR, 1.62; 95% CI,
1.02-2.58; P5 .04) regimens but not Bu or melphalan plus or minus
TT plus or minus FLU. The effect of conditioning regimen was inde-
pendent of donor type. The 5-year probabilities of overall survival for
patients aged#6 years, 7 to 15 years, and 16 to 25 years, adjusted
for donor type and conditioning regimen were 90% (95%CI, 88-93),
84% (95%CI, 80-87), and 63% (95%CI, 45-82), respectively (P,
.001). There were a total of 142 deaths. Infection (34%), GVHD
(24%), and graft failure (13%) were the main causes of death. Other
causes of death included veno-occlusive disease (6%), interstitial
pneumonitis (3%), organ failure (11%), hemorrhage (7%), secondary
malignancy (1%), and other causes (1%).
Graft failure
Ninety-nine patients reported graft failure; 56 were primary graft
failure and 43 were secondary graft failure. The median time
to secondary graft failure was 83 days (interquartile range, 42-
220 days). Older age at transplantation and HLA-mismatched
donor transplantations were associated with higher risk for graft
failure. Patients older than 15 years at transplantation were at higher
risk for graft failure compared with those #6 years (Table 4) and
those aged 7 to 15 years (HR, 2.33; 95% CI, 1.04-5.26; P 5 .04).
Graft failure was higher after HLA-mismatched relative compared
with HLA-matched relative transplantation (Table 4). Graft failure
was also higher after HLA-mismatched relative compared with
HLA-matched unrelated donor (HR, 4.69; 95% CI, 2.27-9.67;
P , .0001) and HLA-mismatched unrelated donor (HR, 2.17;
95% CI, 1.01-4.66; P 5 .05) transplantation. Similarly, graft
failure was higher after HLA-mismatched unrelated compared
with HLA-matched unrelated donor transplantation (HR, 2.17;
95% CI, 0.96-4.76; P 5 .06). Graft failure was lower with in vivo
T-cell depletion (HR, 0.46; 95% CI, 0.30-0.70; P 5 .003).
However, in vivo T-cell depletion was strongly correlated with age in
that 80% of patients aged ,7 years and 67% of patients aged
7 to 15 years received in vivo T-cell depletion compared with
58% of patients aged 16 to 25 years. The 5-year probability of
graft failure by age at transplantation and donor type is shown
in Figure 3.
GVHD
Grade II-IV acute GVHD was higher in older patients, after
transplantation of grafts from donors other than HLA-matched
related donors and transplantations prior to 2012 (Table 4).
Grade II-IV acute GVHD risks were not different between
HLA-mismatched related, HLA-matched, and HLA-mismatched
unrelated donor transplants (data not shown). In vivo T-cell
depletion was not associated with grade II-IV acute GVHD (HR,
0.73; 95% CI, 0.43-1.26; P 5 .26). Age and donor type were
also associated with grade III-IV acute GVHD. Grade III-IV acute
GVHD was higher in patients aged 16 to 25 years compared
with those aged ,7 years (HR, 3.41; 95% CI, 1.40-8.28; P 5
.007) and those aged 7 to 15 years (HR, 3.33; 95% CI, 1.32-
8.33; P 5 .01). Compared with HLA-matched related donor,
grade III-IV acute GVHD was higher after HLA-mismatched
related (HR, 4.40; 95% CI, 2.33-8.31; P , .0001), HLA-matched
unrelated (HR, 2.43; 95% CI, 1.45-4.08; P 5 .0007), and
HLA-mismatched unrelated donor (HR, 2.70; 95% CI, 1.38-5.28;
P 5 .004) transplants. In vivo T-cell depletion was not associated
with grade III-IV acute GVHD (HR, 0.70; 95% CI, 0.63-2.18;
P 5 .62).
Chronic GVHD was also higher after transplantation of grafts
from donors other than HLA-matched related donors (Table 4).
Although the risk of chronic GVHD did not differ between HLA-
mismatched related and HLA-matched unrelated donor trans-
plants (HR, 1.24; 95% CI, 0.55-2.78; P 5 .61), risks were higher
after HLA-mismatched unrelated compared with HLA-matched
unrelated donor transplants (HR, 2.00; 95% CI, 1.04-3.85; P 5
.04). As recorded with acute GVHD, chronic GVHD risks were
higher with Bu/Cy/FLU, Bu/Cy, and treosulfan/TT/FLU com-
pared with the Bu/Cy/TT/FLU regimen (Table 3). Compared with
Bu/Cy/FLU, risks were also higher with Bu/Cy (HR, 3.33; 95% CI,
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Figure 2. Overall survival. (A) Overall survival by
age at transplantation The 5-year probabilities of
overall survival for patients aged #6 years, 7 to
15 years, and 16 to 25 years were 90% (88%
to 93%), 84% (80% to 87%), and 63% (45% to
82%), respectively. (B) Overall survival by donor
type. The 5-year probabilities of overall survival
after HLA-matched relative, HLA-mismatched
relative, HLA-matched unrelated, and
HLA-mismatched unrelated donor transplants
were 89% (87% to 91%), 73% (64% to 82%),
87% (81% to 93%), and 83% (74% to 91%),
respectively.
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1.82-6.25; P 5 .0001) and treosulfan/TT/FLU (HR, 3.57; 95% CI,
1.69-7.69; P 5 .0008) regimens. In vivo T-cell depletion was not
associated with chronic GVHD (HR, 1.17; 95% CI, 0.63-2.18;
P 5 .62).
Subset analysis
In the subset of patients for whom we could assign the Pesaro risk
class (526 of 1110; 47%), treatment failure and overall mortality
were higher for risk class II and III after adjusting for age at
transplant, donor type, and conditioning regimen. Compared
with risk class I, event-free survival was lower for risk class II
(HR, 4.86; 95% CI, 1.86-12.72; P 5 .001) and for risk class III
(HR, 4.76; 95% CI, 1.92-11.76; P , .0001). The corresponding
hazards for overall survival were HR, 3.42; 95% CI, 1.03 to 11.29;
P 5 .04 and HR, 5.41; 95% CI, 1.97 to 14.91; P 5 .001.
Discussion
We report on recent transplantations for b-thalassemia major
outside of Europe, Iran, and Saudi Arabia.3 The current report
extends our knowledge of transplantation for b-thalassemia major
by including transplantations between 2012 and 2016, a period not
previously reported by others. This allowed us to study outcomes
after HLA-mismatched related donor and unrelated donor trans-
plantation relative to outcomes after matched related donor trans-
plantation, not previously reported.We confirm age at transplantation
and donor type predict event-free survival, overall survival, and graft
failure. The adverse effect of older age on event-free and overall
survival confirm and extend published reports for b-thalassemia
major6,9-11,21,22 and sickle cell disease.23 However, unlike most
reports that have identified lower survival in patients older than
15 years, we identified 2 clinically relevant ages at transplantation,
6 years and 15 years that predict differences in event-free and
overall survival. Graft failure was also substantially higher for
patients older than 15 years at transplantation, underscoring the
need for early transplantation if this treatment modality is being
considered. With 5-year event-free survival of 86% for patients
aged #6 years, 80% for patients aged 7 to 15 years, and 63%
for patients aged 16 to 25 years, the optimal age for transplantation
is #6 years. Most patients in the current analyses were inade-
quately chelated and consequently more likely to have hepatomeg-
aly and portal fibrosis with increasing age. Inadequate chelation,
hepatomegaly, and portal fibrosis are risk factors associated
with allogeneic transplantation.24 Ours is the first report to
demonstrate comparable event-free and overall survival after
HLA-matched related and HLA-matched unrelated donor
transplantation. Thus, our findings support initiating simulta-
neous search for HLA-matched related and unrelated donors
early in the course of the disease, and transplantation be-
ing offered with an HLA-matched unrelated donor if an HLA-
matched sibling is not available. Delaying transplantation
beyond 15 years results in a 20% to 25% absolute decrement
in event-free and overall survival. Although event-free and
overall survival were lower after mismatched related and
unrelated donor transplantation, our data support 1 HLA locus
mismatched unrelated donor instead of an HLA-mismatched
relative. Graft failure was highest after transplantation of
grafts from an HLA-mismatched relative, and an absolute
decrement of 10% to 15% in event-free survival in patients
aged #6 years and 7 to 15 years after transplantation of grafts
from HLA-mismatched relative compared with HLA-mismatched
unrelated donor cannot be ignored.
The 3 predominant conditioning regimens in the current analyses
were Bu/Cy/TT/FLU, Bu/Cy/ FLU, and Bu/Cy accounting for 80%
of transplantations. Although we recorded higher overall and event-
free survival with Bu/Cy/TT/FLU and Bu/Cy/FLU regimens com-
pared with the Bu/Cy regimen, the choice of conditioning regimen
was directed by transplant center practice and/or physician choice.
Table 4. Risks factors for graft failure, grade II-IV acute and chronic
GVHD
Outcomes Events/evaluable HR (95% CI) P
Graft failure
Age at transplantation, y
#6 49/638 1.00 .02
7-15 43/439 1.30 (0.86-1.96) .21
16-25 7/33 3.03 (1.36-6.73) .006
Donor type
HLA-matched relative 58/677 1.00 ,.001
HLA-mismatched relative 17/78 2.84 (1.65-4.88) ,.001
HLA-matched unrelated 13/252 0.61 (0.33-1.11) .10
HLA-mismatched unrelated 11/103 1.31 (0.68-2.50) .42
Acute GVHD
Age at transplantation, y
#6 93/634 1.00 .002
7-15 78/436 1.10 (0.71-1.70) .66
16-25 10/33 2.23 (1.30-3.84) .003
Donor type
HLA-matched relative 80/674 1.00 ,.001
HLA-mismatched relative 27/77 3.33 (2.15-5.17) ,.001
HLA-matched unrelated 54/251 2.44 (1.72-3.46) ,.001
HLA-mismatched unrelated 20/101 1.94 (1.19-3.16) .008
Transplant period
2012-2016 85/653 1.00 ,.001
2006-2011 68/338 1.70 (1.23-2.35) .001
2000-2005 28/112 2.50 (1.61-4.00) ,.001
Chronic GVHD
Donor type
HLA-matched relative 52/627 1.00 ,.001
HLA-mismatched relative 14/70 2.64 (1.42-4.89) .002
HLA-matched unrelated 21/249 2.13 (1.13-4.00) .02
HLA-mismatched unrelated 24/101 4.25 (2.43-7.44) ,.001
Conditioning regimen
Bu/Cy/TT/FLU 17/372 1.00 ,.001
Bu/Cy/FLU 24/255 2.03 (1.09-3.78) .03
Bu/Cy 41/223 6.78 (3.59-12.81) ,.001
Treosulfan/TT/FLU 20/140 7.25 (3.41-15.41) ,.001
Bu or melphalan 6 TT 6 FLU 9/57 1.94 (0.82-4.60) .13
Recipient sex
Male 82/659 1.00
Female 29/388 0.59 (0.38-0.91) .02
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The excellent survival reported with Bu/Cy/TT/FLU is consistent
with that reported from a single center.4 However, the majority
of patients who received the Bu/Cy/TT/FLU in the current
analyses were also transplanted at that center and may in part
be attributed to center practice. In contrast, the Bu/Cy/FLU and
Bu/Cy regimens were used in many more transplant centers
and were more representative of clinical practice. The recorded
higher overall and event-free survival after Bu/Cy/FLU com-
pared with Bu/Cy cannot be attributed to age at transplantation
or donor type. Approximately 60% of patients who received Bu/
Cy/FLU and Bu/Cy were aged #6 years and 85% of patients
who received the Bu/Cy regimen received grafts from an HLA-
matched sibling compared with 50% of patients who received
the Bu/Cy/FLU regimen. We hypothesize that the additional
immunosuppression with the addition of FLU to Bu/Cy resulted
in sustained donor engraftment and lower acute and chronic
GVHD that resulted in higher overall and event-free survival.
Others have reported excellent survival with the treosulfan/TT/
FLU regimen5 and a single-center report recorded a survival
advantage with treosulfan/TT/FLU compared with the Bu/Cy
regimen in older patients.6 Our observations differ in that
overall and event-free survival were substantially lower with the
treosulfan/TT/FLU regimen compared with the Bu/Cy/FLU regimen.
However, in our population, the treosulfan/TT/FLU regimen was
used almost exclusively for older patients and those with Pesaro
class III, making it a challenge to study this regimen in the context of
the current analysis.
Although the data support an HLA-matched sibling as the ideal
donor, availability is limited and strategies to overcome higher acute
and chronic GVHD with alternative donors are highly desirable.
Higher acute GVHD after mismatched related and unrelated donor
transplants compared with matched sibling transplants is consis-
tent with reports on the effect of donor-recipient HLA match on
acute GVHD risks.25 Similarly, higher chronic GVHD after unrelated
donor transplantation is also consistent with that reported by
others.26 Grade II-IV and III-IV acute GVHD were higher in older
patients consistent with published reports.27 With most patients in
the current analyses aged ,16 years, we were unable to record an
effect of age on chronic GVHD.28
To our knowledge, this is the first study to analyze a large number
of transplants for b-thalassemia that compared HLA-matched
sibling and alternative donor transplants. Yet, there are limitations.
We studied transplant strategies including timing, donor selec-
tion, and conditioning regimen retrospectively. Consequently, there
are several unknown or unmeasured factors that may have influ-
enced the findings reported herein. We were unable to study an
effect of graft type in the current analyses. Graft correlated with
transplant-conditioning regimen and the regimen (Bu/Cy/TT/FLU)
most likely to use peripheral blood was not associated with lower
event-free or overall survival. There are also limitations to conduct-
ing large-scale prospective clinical trials primarily attributed to costs
and lengthy accrual periods.
A chronic transfusion program coupled with adherence to chelation
and advances in supportive care has ensured that patients with
thalassemia major are living longer with good quality of life.24,29,30
The decision to offer transplantation is determined by the treating
physician in consultation with the patient and his or her family. If
transplantation is determined as the treatment of choice for a given
patient, with 5-year event-free survival approaching 90% after
HLA-matched sibling and HLA-matched unrelated donor, the
data support transplantation with either donor type in patients
aged #6 years. Transplantation for older patients particularly those
older than 15 years and with mismatched related or mismatched
unrelated donors is less desirable and requires a careful evalua-
tion of survival with best available treatment vs transplantation.
Collectively, our data do not support the Bu/Cy regimen and favor
the Bu/Cy/FLU regimen. However, we acknowledge that identify-
ing an optimal conditioning regimen is best studied in the setting of
carefully controlled prospective trials.
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Figure 3. Graft failure. (A) Graft failure by age at
transplantation. The 5-year probabilities of graft
failure for patients aged #6 years, 7 to 15 years,
and 16 to 25 years were 8% (6% to 10%), 10%
(7% to 12%), and 22% (7% to 34%), respectively.
(B) Graft failure by donor type. The 5-year probabili-
ties of graft failure after HLA-matched relative,
HLA-mismatched relative, HLA-matched unrelated,
and HLA-mismatched unrelated donor transplants
were 9% (6% to 11%), 21% (12% to 29%), 6%
(3% to 9%), and 11% (5% to 18%), respectively.
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